Fighting the world’s most devastating diseases through the innovative power of targeted oral mRNA vaccines.
Our Vision
Esperovax aspires to become the global leader in targeted oral tablet and capsule vaccinations for many of the world's deadliest treatable diseases.
Our Mission
Esperovax looks to be the leader in oral mRNA-based vaccines and biotherapeutics to provide rapid, painless, and inexpensive biological medicines that make a significant impact on global health.
Our History
Esperovax is a biotechnology company based in Plymouth, MI. The company has developed a novel mRNA oral vaccine platform that will enable large-scale production and distribution of shelf-stable vaccines at a fraction of the cost of current injection-based treatments.
Esperovax traces its roots to the relationship formed between founders Roger Newton, Savita Nikam, and David O’Hagan through an Undergraduate Biological Research Program, where they successfully trained more than 100 students from 2011-18. David and Savita formed Tempo Probiotics to develop commercial technologies for the microbiome market. They began exploring novel methods of using genetically modified probiotics to deliver therapeutics in a more natural, inexpensive manner. The Egress 1 protein was found to allow virus-like particle secretion from yeast. Roger joined the enterprise as together the team drove proof-of-concept experiments in mice, licensing the technology to the newly formed Esperovax in 2020.
